NCT03137160View on ClinicalTrials.gov

An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 4, 2017

Primary Completion Date

August 16, 2018

Study Completion Date

August 16, 2018

Conditions
Pyoderma Gangrenosum
Interventions
BIOLOGICAL

Ixekizumab

Injection

Trial Locations (1)

43230

The Ohio State University Dermatology, Gahanna

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Ohio State University

OTHER

NCT03137160 - An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | Biotech Hunter | Biotech Hunter